Anti-Inflammatory Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Anti-inflammatory Biologics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids), By Indication (Arthritis, Anti-inflammatory Bowel Disease (IBD), Respiratory Disease, Multiple Sclerosis, Psoriasis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Providers) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Anti-Inflammatory Therapeutics Market Size

The global anti-inflammatory therapeutics market size was valued at USD 115.79 billion in 2025 and is projected to grow from USD 119.95 billion in 2026 to USD 159.05 billion by 2034, registering a CAGR of 3.59% during the forecast period from 2026 to 2034. North America dominated the anti-inflammatory therapeutics market with a market share of 38.4% in 2025.

Anti-inflammatory therapeutics are medications designed to reduce inflammation, a natural response by the body to injury, infection, or conditions such as arthritis and inflammatory bowel disease (IBD). The major factors contributing to the growth of the global anti-inflammatory therapeutics market are the increasing prevalence of inflammatory diseases, ongoing technological advancements in drug delivery systems, and a growing number of regulatory approvals for anti-inflammatory therapeutics.

These drugs target pathways involved in inflammation to alleviate pain, swelling, and tissue damage. Common categories of anti-inflammatory drugs include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologics. By reducing inflammation, these therapeutics help manage chronic conditions, improve quality of life, and prevent further complications from prolonged inflammation.

Segmentation Analysis

The global anti-inflammatory therapeutics market is segmented into drug class, indication, and distribution channel.

By Drug Class

Anti-inflammatory biologics segment dominates the market with the largest market revenue

The anti-inflammatory biologics segment leads the market, driven by their effectiveness in treating chronic inflammatory conditions. Drugs like TNF inhibitors and interleukin inhibitors target specific immune molecules to reduce inflammation, providing relief for patients with conditions unresponsive to NSAIDs or corticosteroids. The rising prevalence of autoimmune disorders and the approval of new biological therapies further boost demand.

• For example, AbbVie’s SKYRIZI (risankizumab-rzaa) was approved by the U.S. FDA in June 2024 for ulcerative colitis treatment, expanding its therapeutic options.

Request Customizationto receive a tailored report.

By Indication

Arthritis segment dominates the market with the largest market revenue

Arthritis holds the largest share of the global market due to the growing prevalence of the condition and the effectiveness of anti-inflammatory treatments. Therapies, particularly biologics, have been instrumental in managing symptoms and improving the quality of life for patients.

• In February 2023, the FDA approved Regeneron Pharmaceuticals’ Kevzara (sarilumab) for treating polymyalgia rheumatica (PMR), an inflammatory rheumatic disease. The increasing awareness and availability of advanced therapies, including biologics, are key factors driving market growth.

By Distribution Channel

Hospital pharmacies segment dominates the market with the largest market revenue

Hospital pharmacies dominate the global market primarily due to their role in managing biologic treatments and advanced therapies. Hospitals provide the specialized infrastructure needed for storing and administering biologics, ensuring proper handling and patient care. As treatment centers for severe conditions like rheumatoid arthritis and ulcerative colitis, hospital pharmacies offer expertise in prescribing these advanced medications. Their pivotal role in the treatment of chronic inflammatory conditions solidifies their leadership in the market.

Speak to an Analystto discuss market opportunities.

Countries Insights

North America

• U.S. – The U.S. market thrives on its advanced healthcare infrastructure, substantial health expenditure, and leading pharmaceutical research. The widespread prevalence of inflammatory conditions such as arthritis and IBD further fuels growth. For example, in June 2024, Amgen presented 27 abstracts at the European Alliance of Associations for Rheumatology's (EULAR) Congress, showcasing its commitment to developing novel therapies for inflammatory and rheumatic diseases.

• Canada – Canada’s market is expanding due to improved healthcare access, a large patient population, and increasing cases of autoimmune and inflammatory diseases. In October 2024, Crohn’s & Colitis Canada reported that over 322,000 Canadians are affected by Crohn’s disease or ulcerative colitis, with numbers expected to rise to 470,000 by 2035. This growing patient pool contributes significantly to demand for targeted treatments.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe

• Germany – Germany's market is driven by its emphasis on healthcare innovation and high demand for advanced therapies. The country's focus on developing new treatments for chronic inflammatory conditions, coupled with strong investment in research, fuels market expansion. Germany also benefits from a well-established healthcare system that supports the adoption of innovative anti-inflammatory biologics.

• UK – In the UK, rising awareness and acceptance of innovative therapies among healthcare professionals and patients are propelling demand for anti-inflammatory therapeutics. Additionally, growing demand for biologics and advancements in immunology research support growth. For instance, in February 2024, Queen Mary University of London researchers reported findings related to RvT4 and natural defenses against atherosclerosis in rheumatoid arthritis patients.

• France – France's anti-inflammatory therapeutics market is influenced by the increasing number of patients with chronic inflammatory diseases. A growing focus on improving treatment of these conditions contributes to expansion. For example, in October 2024, Université de Lille reported that chronic inflammatory diseases affect 4 million people in France, highlighting the substantial healthcare burden associated with these conditions.

Asia-Pacific

• China – China's market is expanding due to rapid urbanization, rising healthcare expenditure, and innovative research. The country's large population and growing health awareness further support growth. In July 2024, Everest Medicines treated its first Chinese patient with zetomipzomib, a novel immunoproteasome inhibitor for lupus nephritis, in the Phase 2b PALISADE trial.

• Japan – Japan’s aging population and increasing prevalence of inflammatory diseases, including inflammatory bowel disease, arthritis, and respiratory conditions, are driving demand. The need for advanced therapies to manage these conditions continues to increase as Japan addresses the healthcare requirements of its aging demographic. Treatment innovation, particularly in biologics and immunotherapy, is further supporting development.

• India – In India, demand is growing due to the rising prevalence of autoimmune and chronic diseases, an aging population, and lifestyle changes. Improved healthcare access, greater awareness, and expanding availability of biosimilars are contributing to growth. India’s strong pharmaceutical manufacturing sector and government support also help improve access to advanced treatments. In January 2023, Sun Pharma's acquisition of three drug brands expanded its anti-inflammatory portfolio.

List of Key and Emerging Players in Anti-Inflammatory Therapeutics Market